Thu, 10th Jan 2019 12:35
LONDON (Alliance News) - Diurnal Group PLC said on Thursday that, aside from the granting of a patent, it is unsure as to why its share price has tripled.
Shares were 188% higher on Thursday at 62.00 pence each, having earlier hit 78.20p.
The US Patent & Trademark Office has granted Diurnal a second US patent for Chronocort, a cortisol replacement product for the life-long treatment of congenital adrenal hyperplasia and adrenal insufficiency.
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
(Alliance News) - Diurnal Group PLC on Friday said its Efmody treatment has been recommended as an option to treat patients with congenital adrenal hy...
(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Friday that the All-Wales Medicines Strategy Group (AWMSG) has recommen...